10% Off
Carvista12.5 mg
Incepta Pharmaceuticals Ltd.
৳45.00
Add to cart
Cardivas12.5 mg
Tablet
By
Best PriceTk /
Out Of Stock1
Alternatives
Price
Medicine overview
Indications of Cardivas 12.5 mg
Cardivas 12.5 mg is indicated for the treatment of mildmoderate or severe heart failure of ischemic or cardiomyopathic originin conjunction with digitalisdiuretics and ACE inhibitorto reduce the progression of disease as evidenced by cardiovascular deathcardiovascular hospitalizationor the need ... Read moreCardivas 12.5 mg is indicated for the treatment of mildmoderate or severe heart failure of ischemic or cardiomyopathic originin conjunction with digitalisdiuretics and ACE inhibitorto reduce the progression of disease as evidenced by cardiovascular deathcardiovascular hospitalizationhydralazine or nitrate therapy.
Theropeutic Class
Alpha adrenoceptor blocking drugs, Beta-adrenoceptor blocking drugs, Beta-blockers
Pharmacology
Cardivas 12.5 mg is a non selective β-adrenergic blocking agent which causes vasodilation by blocking the activity α-1 receptors.
Absorption
It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation.
Dosage & Administration of Cardivas 12.5 mg
Hypertension
Dosage:Initially 12.5 mg once daily, increased after 2 days to usual dose of 25 mg once daily; if necessary may be further increased at intervals of at least 2 weeks to max.50 mg daily in single or divided doses; Elderly: Initial dose of 12.5 mg daily may provide satisfactory control
Angina
Dosage:Initially 12.5 mg twice daily, increased after 2 days to 25 mg twice daily
Heart failure (under special supervision)
Dosage:Initially 3.125 mg twice daily (with food), dose increased at intervals of at least 2 weeks to 6.25 mg twice daily, then to 12.5 mg twice daily, then to 25 mg twice daily, increase to highest dose tolerated, maximum 25 mg twice daily in patients with severe heart failure or body-weight less than 85 kg and 50 mg twice daily in patients over 85 kg
| Condition | Dosage | Notes |
|---|---|---|
| Hypertension | Initially 12.5 mg once daily, increased after 2 days to usual dose of 25 mg once daily; if necessary may be further increased at intervals of at least 2 weeks to max.50 mg daily in single or divided doses; Elderly: Initial dose of 12.5 mg daily may provide satisfactory control | |
| Angina | Initially 12.5 mg twice daily, increased after 2 days to 25 mg twice daily | |
| Heart failure (under special supervision) | Initially 3.125 mg twice daily (with food), dose increased at intervals of at least 2 weeks to 6.25 mg twice daily, then to 12.5 mg twice daily, then to 25 mg twice daily, increase to highest dose tolerated, maximum 25 mg twice daily in patients with severe heart failure or body-weight less than 85 kg and 50 mg twice daily in patients over 85 kg |
Dosage of Cardivas 12.5 mg
In hypertension
Dosage:initially, 12.5 mg once daily, increased after 2 days to the usual dose of 25 mg once daily; if necessary the dose may be further increased at intervals of at least 2 weeks to maximum 50 mg daily in single or divided doses
Notes:In elderly patients, the initial dose of 12.5 mg daily may provide satisfactory control
In angina pectoris
Dosage:the recommended dose for initiation of therapy is 12.5 mg twice daily for the first 2 days
Notes:Thereafter, the recommended dosage is 25 mg twice daily. For elderly patients, the maximum daily dose is 50 mg daily in divided doses
In heart failure
Dosage:initially, 3.125 mg twice daily (with food) may be given, the dose may be increased at intervals of at least 2 weeks to 6.25 mg twice daily, then to 12.5 mg twice daily, then to 25 mg twice daily
Notes:The dose may be increased to the highest dose tolerated, maximum 25 mg twice daily in patients less than 85 kg body-weight and 50 mg twice daily in patients over 85 kg
| Condition | Dosage | Notes |
|---|---|---|
| In hypertension | initially, 12.5 mg once daily, increased after 2 days to the usual dose of 25 mg once daily; if necessary the dose may be further increased at intervals of at least 2 weeks to maximum 50 mg daily in single or divided doses | In elderly patients, the initial dose of 12.5 mg daily may provide satisfactory control |
| In angina pectoris | the recommended dose for initiation of therapy is 12.5 mg twice daily for the first 2 days | Thereafter, the recommended dosage is 25 mg twice daily. For elderly patients, the maximum daily dose is 50 mg daily in divided doses |
| In heart failure | initially, 3.125 mg twice daily (with food) may be given, the dose may be increased at intervals of at least 2 weeks to 6.25 mg twice daily, then to 12.5 mg twice daily, then to 25 mg twice daily | The dose may be increased to the highest dose tolerated, maximum 25 mg twice daily in patients less than 85 kg body-weight and 50 mg twice daily in patients over 85 kg |
Interaction of Cardivas 12.5 mg
Digoxin—: In normal healthy volunteers a single dose of Cardivas 12.5 mg taken together with a single dose of digoxin resulted in significantly increased levels of digoxin 24 hours later
Patients with congestive heart—failure stabilized on digoxin have been given Cardivas 12.5 mg concomitantly without any adverse effects
Increased monitoring of digoxin—is recommended when initiating, adjusting, or discontinuing the dose of Cardivas 12.5 mg
Rifampin—: Pretreatment with rifampin resulted in a 60% decrease in Cmax and AUC
Warfarin—: Cardivas 12.5 mg did not alter the in vitro plasma protein binding of warfarin
Clonidine—: β-receptor antagonists potentiate the pressor reaction which may follow the sudden withdrawal of treatment with clonidine although, in theory, the a-blocking action of Cardivas 12.5 mg should modify the pressure rise
Contraindications
Cardivas 12.5 mg is contraindicated in patients with decompensated heart failure requiring intravenous inotropic therapy, bronchial asthma or related bronchospastic conditions, second or third-degree AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia.
Side Effects of Cardivas 12.5 mg
Common (>1%)
- Postural hypotension
- dizziness
- headache
- fatigue
- gastro-intestinal disturbances
- bradycardia
- occasionally diminished peripheral circulation
- peripheral oedema and painful extremities
- dry mouth
- dry eyes
Uncommon
- eye irritation or disturbed vision
- impotence
- disturbances of micturition
- influenza-like symptoms
- rarely angina
- AV block
- exacerbation of intermittent claudication or Raynaud's phenomenon
- allergic skin reactions
- exacerbation of psoriasis
- nasal stuffiness
Rare / Long-term
- wheezing
- depressed mood
- sleep disturbances
- paresthesia
- heart failure
- changes in liver enzymes
- thrombocytopenia
- leukopenia are also reported.
Pregnancy & Lactation
Cardivas 12.5 mg should not be used during pregnancy as no studies have been performed in this group. Cardivas 12.5 mg and its metabolites are excreted in breast milk. Therefore, breastfeeding is not recommended during administration of Cardivas 12.5 mg.
Precautions & Warnings
Take caution in hepatic impairment and in heart failure monitor clinical status for 2-3 hours after initiation and after increasing each dose. Before increasing dose ensure that the renal function and heart failure are not deteriorating
Overdose Effects of Cardivas 12.5 mg
Symptoms: Severe hypotension, bradycardia, heart failure, cardiogenic shock and cardiac arrest. Resp problems, bronchospasms, vomiting, lapses of consciousness and generalised seizures. Management: Symptomatic and supportive treatment. Consider use of atropine for excessive bradycardia, IV glucagon or sympathomimetics to support ventricular function. Consider using norfenephrine or noradrenaline if vasodilation dominates the intoxication profile and IV inj of diazepam or clonazepam for seizures.
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Use In Special Populations
The safety and efficacy of Cardivas 12.5 mg in paediatric patients have not been established.
Drug Classes
Alpha adrenoceptor blocking drugs, Beta-adrenoceptor blocking drugs, Beta-blockers
Mode Of Action
Cardivas 12.5 mg is a cardiovascular drug whose main pharmacological action is non-selective antagonism of β-adrenergic receptors but which also possesses appreciable a-adrenergic antagonistic activity. It also has antiproliferative properties and is a scavenger of reactive free oxidant radicals. It is used in the treatment of hypertension, angina pectoris and congestive heart failure.
Pregnancy
Cardivas 12.5 mg should not be used during breast-feeding, since no studies have been performed in lactating women and animal studies have shown that Cardivas 12.5 mg is excreted in breast milk. Safety and efficacy in children have not been established with Cardivas 12.5 mg. Cardivas 12.5 mg should not be used during pregnancy as no studies have been performed in this group. Animal studies have shown that Cardivas 12.5 mg crosses the placental barrier. No information is available on the safety and efficacy of Cardivas 12.5 mg use in neonates.
Frequently Asked Questions
What is Cardivas 12.5 mg used for?
Carvedilol is indicated for the treatment of mild, moderate or severe heart failure of ischemic or cardiomyopathic origin, in conjunction with digitalis, diuretics and ACE inhibitor, to reduce the progression of disease as evidenced by cardiovascular death, cardiovascular hospitalization, or the need ... Read moreCarvedilol is indicated for the treatment of mild, moderate or severe heart failure o…
What is the dosage of Cardivas 12.5 mg?
In hypertension: initially, 12.5 mg once daily, increased after 2 days to the usual dose of 25 mg once daily; if necessary the dose may be further increased at intervals of at least 2 weeks to maximum 50 mg daily in single or divided doses. In elderly patients, the initial dose of 12.5 mg daily may provide satisfactory control.In angina pectoris: the recommended dose for initiation of therapy is 1…
What are the side effects of Cardivas 12.5 mg?
Postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, AV block, exacerbation of intermittent claudication or Raynaud's phenomenon…
Who should not take Cardivas 12.5 mg?
Carvedilol is contraindicated in patients with decompensated heart failure requiring intravenous inotropic therapy, bronchial asthma or related bronchospastic conditions, second or third-degree AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia.
What precautions should be taken with Cardivas 12.5 mg?
Take caution in hepatic impairment and in heart failure monitor clinical status for 2-3 hours after initiation and after increasing each dose. Before increasing dose ensure that the renal function and heart failure are not deteriorating
Is Cardivas 12.5 mg safe during pregnancy and breastfeeding?
Carvedilol should not be used during pregnancy as no studies have been performed in this group. Carvedilol and its metabolites are excreted in breast milk. Therefore, breastfeeding is not recommended during administration of Carvedilol.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.